FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab

摘要: Purpose Cetuximab, a chimeric immunoglobulin G 1 (IgG1) anti–epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), has shown efficacy in 10% of patients with metastatic colorectal cancer (CRC). Recent studies demonstrate antibody-dependent cell-mediated cytotoxicity (ADCC) is one the modes action for rituximab and trastuzumab. Fragment c (Fc) portion IgG1 mAb to induce ADCC. gamma receptors (FcγR) play an important role initiating Studies have that two IgG FcγR polymorphisms (FCGR2A-H131R FCGR3A-V158F) independently predict response follicular lymphoma. We tested hypothesis whether these are associated clinical outcome CRC treated single-agent cetuximab. Patients Methods Thirty-nine were enrolled onto ImClone0144 trial. Using allele-specific polymerase chain reaction (PCR) –based method, gene FCGA2A-H131R a...